RBC on Beam Therapeutics Inc (BEAM): 'we view the data as incrementally positive'

March 25, 2026 11:48 AM

RBC Capital analyst Luca Issi reiterated a Sector Perform rating and $26.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found